Background {#Sec1}
==========

External beam radiotherapy or radio-chemotherapy is commonly employed in both curative and palliative treatment for non-small cell lung cancer. Several factors influence the outcome of these patients, including TNM stage, age, gender, histologic type of the tumor, radiation dose and the overall radiation treatment time. Precise assessment of the prognosis is essential for adequate selection of treatment strategy and for proper stratification of individuals within prospective trials. Numerous attempts have been made to improve well-established prognostic models that are based on the assessment of clinicopathological features. These attempts include the analysis of circulating tumor cells \[[@CR1]\], circulating cell-free tumor DNA \[[@CR2]\], gene expression profiles from bronchoscopy obtained tumor samples \[[@CR3]\], the analysis of common somatic mutations and rearrangements in specific genes including EGFR, ALK, ROS1, Her2, BRAF, KRAS, PTEN \[[@CR4]\] and the analysis of blood serum proteins \[[@CR5]\]. The literature on this subject is extensive hence we herein refer to review studies on the relevant topic \[[@CR1], [@CR2], [@CR4], [@CR5]\]. We also note that, apart from prognostic utility, blood biomarkers are heavily tested as potential diagnostic markers in the early detection of lung cancer \[[@CR6], [@CR7]\].

Most of the studies note that, considering advanced inoperable cases, the amount of tumor tissue in bronchoscopy obtained tumor samples is scarce and, in most circumstances, cautiously stored for assessment of the molecular and pathological biomarkers that are necessary for proper selection of the modern systemic treatment (PDL-1 expression, EGFR and ROS mutations, ALK rearrangement etc..). This finding provides the basic rationale for the analysis of blood biomarkers, because the blood samples can be readily obtained both before, during and after radiotherapy and this process does not interfere with assessment of the tumor biomarkers that are now heavily utilized in medical oncology.

While the literature on the diverse utility of the biomarkers in lung cancer is broad, relatively few studies have directly focused on assign of the independent prognostic value of blood serum proteins as biomarkers of the long-term prognosis in radiotherapy and radio-chemotherapy for non-small cell lung cancer. Nonetheless, the existing studies document that such an approach is promising and may considerably improve basic clinically-oriented prognostic models \[[@CR8]--[@CR10]\]. However, the practical significance and utility of blood serum markers may largely depend on the clinical and therapeutic characteristics of the group of patients. Therefore, we analyzed the selected blood markers in a large group of patients with non-small cell lung cancer treated with radiotherapy or radio-chemotherapy focusing on the utility of these markers in the homogenous subsets, compared to significance in a large heterogeneous group.

Methods {#Sec2}
=======

General characteristics of the patients {#Sec3}
---------------------------------------

Between September 2006 and May 2015 blood samples from 337 patients who were referred for curative or palliative external beam thoracic radiotherapy for non-small cell lung cancer were collected. Patients who had surgery for lung cancer were excluded. Likewise, patients who did not have thoracic radiotherapy were excluded. The group was heterogeneous with respect to the stage of disease, tumor pathology and general performance status (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of 337 patients (including prognostic significance of the selected variables)VariableCategories (No)3-year OS*p*-value\
*(HR)*3-year LRC*p*-value\
*(HR)*3-year MFS*p*-value\
*(HR)*Age\< 6515921.3%**0.02**57.5%0.4036.3%0.23≥6517816.1%***(1.34)***54.0%*(1.21)*40.3%*(0.81)*SexM26016.1%**0.02**55.6%0.6436.7%0.23F7729.6%***(0.70)***57.5%*(0.88)*44.9%*(0.77)*Histologysquamous20614.8%**0.02 \***49.1%**0.02 \***41.2%0.23 \*adeno5031.9%***(0.64)***82.4%***(0.36)***35.5%*(1.32)*NOS8124.6%52.3%32.8%T stage1--212022.2%**\< 0.001**62.4%0.0442.9%**0.02**3--420116.6%***(1.61)***48.3%*(1.61)*36.8%***(1.57)***N/A16N stage0--17117.6%0.8664.2%0.1336.9%0.362--325020.2%*(1.03)*54.2%*(1.59)*41.4%*(1.23)*N/A16M stage026021.2%**\< 0.001**55.2%0.9547.9%***\< 0.001***1688.6%***(1.78)***65.7%*(1.02)*0.0%***(8.7)***N/A9ZUBROD0--130619.6%**0.015**55.6%0.2337.4%0.432--33119.4%***(1.72)***61.3%*(1.60)*60.9%*(0.72)*Radiotherapy\< 60 Gy18910.1%**\< 0.001**49.6%**0.004**19.4%**\< 0.001**≥60 Gy14830.6%***(0.38)***61.5%***(0.52)***35.9%***(0.29)***Smoking statusnever2261.6%**\< 0.001**81.5%**0.04**46.8%0.21ever31417.3%***(3.66)***53.2%***(4.45)***38.2%*(1.54)*Chemotherapyno12412.7%**\< 0.001**53.5%**0.02**42.0%**0.009**yes21323.7%***(0.43)***57.1%***(0.55)***28.8%***(0.61)***\*comparison between squamous cell cancer and adenocarcinomaSignificance (*p*-value, HR) refers to the univariable Cox regression analysis, 3-year OS, LRC and MFS in the respective groups are also presented

The median age of the patients was 65 years, there were 260 males (77.2%) and 77 females (22.8%). Squamous cell cancer was diagnosed in 206 patients (61.1%), adenocarcinoma in 50 patients (14.8%) and NOS in 81 individuals (24.1%). Most of the patients (90.8%) had a good performance status (ZUBROD 0--1). An advanced primary tumor stage (T3--4) was diagnosed in 201 patients (59.6%), while 250 patients (74.2%) had an advanced (N2--3) nodal stage. In 68 individuals (20.2) distant metastases were present at the diagnosis (M1).

The proportion of the patients according to the 8th edition of AJCC staging system was as follows: stage I, 16 patients (4.7%); stage II, 16 patients (4.7%); stage IIIA, 106 patients (31.5%); stage IIIB, 123 patients (36.6%); stage IV, 71 patients (21%); and uncertain stage, 5 patients (1.5%). We noted that all patients in stages I and II who were included in the present study were excluded from surgery due to comorbidities or lack of consent: they were treated with radiotherapy alone (stereotactic treatment, 60 Gy in 3--5 fractions). The majority of the patients included in the study (*N* = 229, 68.1%) were in clinical stages IIIA and IIIB. Nevertheless, this group was heterogeneous with respect to general performance and extent of disease and depending on these features 133/229 patients in this group (58.0%) received radiotherapy with curative intent, compared to 96/229 patients (42.0%) who were administered palliative thoracic radiotherapy. We note that several patients in this stage were treated with surgery and, thus, excluded from the present study. Therefore, the group is not representative of general cohorts of the patients with stage IIIA-IIIB disease.

Only 4 out of 71 patients with stage IV disease were administered radiotherapy with curative intent: this treatment was restricted to individuals in good general performance with oligometastatic disease, all others had palliative thoracic radiotherapy.

Radiation treatment {#Sec4}
-------------------

In general, 3 D radiation treatment planning was used, except for individuals with an impaired performance status (ZUBROD 2--3; Table [1](#Tab1){ref-type="table"}) treated with palliative intent, where 2 D planning was allowed. PET/CT was used for 3D radiation treatment planning in all 148 individuals treated with curative intent. For patients treated with palliative intent PET/CT was used for staging and/or planning whenever considered relevant for proper assessment of the extent of disease. Patients were immobilized in a vacuum mattress or thermoplastic mask and treated in the supine position on a linear accelerator.

Thoracic radiotherapy with curative intent (range, 60--74 Gy; median, 69.2 Gy; mean 68.2 Gy) was given to 148 patients (43.9%). The median fraction dose in this group was 1.8 Gy, the mean fraction dose was 2.4 Gy, and the range of the fraction dose was 1.8--20 Gy. The gross tumor volume (GTV) in curatively treated patients included primary tumor and involved mediastinal nodes. CTV added a margin of 0.5--1 cm for subclinical disease, while ITV accounted for respiratory motion and setup uncertainties. Elective nodal radiotherapy was not used in this group.

Thoracic radiotherapy with palliative intent (range 20--54 Gy, median 20 Gy, mean 24.6 Gy) was administered to 189 patients (56.1%). The median fraction dose in this group was 4.0 Gy, and the mean fraction dose was 3.7 Gy. The GTV in palliatively treated patients encompassed the primary tumor and massively enlarged nodes that contributed to symptoms of disease. We note that radiation treatment techniques and dose-fractionation did not change in Gliwice over the period of the present study.

Chemotherapy {#Sec5}
------------

Chemotherapy was prescribed to 213 patients.

Of 148 patients treated with curative intent 131 (88.5%) received induction chemotherapy, i.e., 2--4 courses of a platinum- based doublet (median 4, range 1--6) were prescribed before the administration of radiotherapy. Such a treatment schedule, was demanded by the protocol of the institutional research project on dose- fractionation in sequential treatment.

Of 189 patients treated with palliative intent 82 (43.4%) received chemotherapy as a part of the first-line treatment (median, 4 cycles; range, 1--4). A platinume- based doublet was the most commonly prescribed palliative regimen. In addition, 36 patients (19.0%) treated with palliative intent received chemotherapy at disease progression.

Overall, cis-platine 80 mg/m2 on day 1 and vinorelbine 30 mg/m2 day 1, 8 doses given every 21 days was the most frequently prescribed regimen (155/213 patients, i.e., 72.8%). Cis-platine and gemcitabine were prescribed in 14 patients (6.5%), Cis-platine and etoposide were also prescribed in 14 patients (6.5%). A carboplatine- based doublet was prescribed in 18 patients (8.4%) and other chemotherapy regimens (mostly navelbine in monotherapy) in the remaining 12 individuals (5.6%). In general, chemotherapy was prescribed sequentially with chemotherapy with only 2 individuals (0.9%) receiving concurrent treatment.

Blood markers {#Sec6}
-------------

In general, the selection of biomarker testes was based on a literature search with a particular focus on markers of hypoxia, angiogenesis, immune responses and proliferation, i.e. the processes that determine the tumor response to radiotherapy and, hence, the long-term outcome of radiotherapy-based treatment. Of several markers that were suggested as prognostic biomarkers in lung cancer, we selected the following: OPN, VEGF, EPO, HMGB1, IGF1--1, PDGF.

Osteopontin (OPN) is a protein that interacts with multiple cell surface receptors involved in several physiological and pathological processes including tumorigenesis, immune responses, inflammation, wound healing, bone turnover, and ischemia \[[@CR11]\]. It was demonstrated that OPN might be a useful biomarker in lung cancer therapy \[[@CR12]\]. Its prognostic significance was demonstrated not only in lung cancer patients treated with radiotherapy \[[@CR13]\] but also in patients with early stage disease treated with surgery \[[@CR14]\] or in advanced cases treated with chemotherapy \[[@CR15]\].

Vascular endothelial growth factor (VEGF) is a protein involved in the formation of blood vessels. As a biomarker related to angiogenesis, it has apparent prognostic potential in cancer therapy \[[@CR16]\]. The prognostic utility of VEGF was shown in patients with lung cancer treated with surgery \[[@CR17]\], radiotherapy \[[@CR18]\] and chemotherapy \[[@CR19]\].

Erythropoetin (EPO) is a protein that is secreted by the kidney in response to cellular hypoxia, it stimulates erythropoiesis. The involvement of this biomarker in response to hypoxia is particularly interesting considering the importance of hypoxia for radiation treatment. Additionally, EPO may have a direct growth-promoting effect on cancer cells, a phenomenon of clinical importance in radiotherapy \[[@CR20]\]. The prognostic utility of erythropoetin in therapy for lung cancer was demonstrated in patients treated with radiotherapy \[[@CR21]\] and surgery \[[@CR22]\].

High mobility group box 1 protein (HMGB1) regulates transcription in cells and mediates immune reactions, which are processes of major importance in tumor progression \[[@CR23]\]. This marker was tested mainly for the purpose of the early diagnosis of lung cancer \[[@CR24]\].

Insulin-like growth factor 1 (IGF-1) is a mediator of the effects of growth hormone involved in several growth-promoting effects, including the proliferation of cancer cells \[[@CR25]\]. Its prognostic utility in therapy for lung cancer was suggested by some authors \[[@CR26]--[@CR28]\], although the results are somewhat conflicting.

Platelet-derived growth factor (PDGF) regulates cell growth and division and plays a significant role in angiogenesis) \[[@CR29]\]. Its prognostic utility in therapy for lung cancer has been investigated by a few authors \[[@CR30], [@CR31]\].

The concentrations of the selected proteins in serum (plasma in the case of OPN) were measured by enzyme-linked immunosorbent assay (ELISA) using a Wallac Victor Multi-label Counter. For the assessment of the EPO concentration, chemiluminescence was used. Table [2](#Tab2){ref-type="table"} briefly summarizes the methodology used to assess the biomarker concentration. Human serum/plasma was prepared by centrifuging whole blood at 1000 *g* for 15 min.Table 2Description of the methodology used to assess the biomarker concentrationMarkerTest nameCompanyMethodMaterial /storageMeasurement unitsOPNQuantikine ELISA Human Osteopontin (OPN)R&D SystemsELISAplasma/−80 °C/ng/mlVEGFRayBio Human VEGF ELISA KitRayBiotech,Inc.ELISAserum/−80 °Cpg/mlEPOImmulite 2000 EPOSiemenschemiluminescenceserum/−80 °CmIU/mlHMGB1HMGB1 ELISAIBL International GMBHELISAserum/−80 °Cng/mlIGF1IGF-I ELISADRGInstruments GmbHELISAserum/−80 °Cng/mlPDGFRayBio Human PDGF-BB ELISA KitRayBiotech,Inc.ELISAserum/−80 °Cpg/ml

The blood samples were drawn before treatment, i.e., at the onset of induction chemotherapy, or before the first fraction of radiotherapy in the case of radiation treatment alone. The serum was stored in a refrigerator at − 80 °C.

Blood samples were prospectively collected and all enrolled patients gave their informed consent to participate. Considering limited funds for this research an interim analysis of the prognostic utility of the selected biomarkers was performed after enrolment of the initial 80--100 patients and further measurements were abandoned, providing a lack of independent prognostic potential in the pilot series. For this reason, IGF 1--1 measurements were abandoned considering the strong correlation of this marker with the TNM stage. Likewise, PDGF measurements were abandoned considering the strong correlation of this marker with the T stage and tumor pathology. Some measurements of OPN, VEGF, EPO and HMGB1 are missing (Table [3](#Tab3){ref-type="table"}), mostly due to temporary limitations in the supply of the reagents.Table 3Influence of the selected biomarkers on overall survival (OS), locoregional control (LRC) and metastases-free survival (MFS)Biomarker *(units)*Cut-off(No)3-year OS*p*-value\
*(HR)*3-year LRC*p*-value\
*(HR)*3-year MFS*p*-value\
*(HR)*OPN (*n* = 290) *(ng/ml)*\< 10414528.0%**\< 0.001**60.5%0.1341.7%0.10≥10414516.6%***(1.74)***55.4%*(1.45)*40.2%*(1.36)*VEGF (*n* = 246) *(pg/ml)*\< 36212231.6%**0.001**57.8%0.6642.7%0.20≥36212215.9%***(1.67)***60.1%*(1.12)*36.1%*(1.30)*EPO (*n* = 223) *(mIU/ml)*\< 16.110726.0%**0.04**62.6%0.4748.2%**0.02**≥16.111615.6%***(1.38)***62.1%*(1.24)*26.3%***(1.67)***HMGB1 (*n* = 206) *(ng/ml*)\< 2.857026.7%0.6468.9%0.3938.9%0.64≥2.8520624.6%*(1.09)*54.9%*(1.30)*44.2%*(1.11)*IGF 1--1 (*n* = 98) *(ng/ml)*\< 994916.3%0.8755.1%0.3137.6%0.57≥99499.2%(0.97)21.9%*(1.44)*33.7%*(1.19)*PDGF (*n* = 85) *(pg/ml)*\< 2494220.2%0.2926.5%**0.013**37.1%0.19≥2494313.9%*(1.28)*73.0%***(0.31)***34.5%*(1.57)*Significance (*p*-value, HR) refers to the univariable Cox regression analysis, 3-year OS, LRC and MFS in the respective groups are also presented

We note that all of the markers selected have previously been studied as prognosticators \[[@CR5]--[@CR31]\], but only some of these studies recruited the patients treated with radiotherapy \[[@CR8]--[@CR10], [@CR13], [@CR15], [@CR18], [@CR21], [@CR32]\]. Furthermore, in several studies only one or two biomarkers were studied, thus the independent prognostic value of these biomarkers (confronted with the other markers) could not be accurately evaluated. Likewise, not all of the studies incorporated clinical prognosticators among the variables studies. For this reason the present analysis accounts for both factors (i.e., the potential clinical prognosticators and the potential blood biomarkers).

Statistical analysis {#Sec7}
--------------------

Overall survival (OS), locoregional control (LRC) and metastasis-free survival (MFS) were the major endpoints of the study (Table [1](#Tab1){ref-type="table"}). The same methodology was used in the analysis of these endpoints. The patients were categorized according to the concentrations of the markers, using the median concentration as a cut-off. Such selection was driven by the practical utility and simplicity of this approach in which the same cut-off was used for different endpoints (OS, LRC, MFS). Several other variables of possible prognostic value were also considered in the analysis including age, gender, pathology, TNM stage, ZUBROD performance status, smoking status, use of chemotherapy and use of curative vs. palliative doses of radiotherapy.

Survival curves (OS, LRC, MFS) and the corresponding 3-year actuarial survival rates were estimated using the Kaplan-Meier method. Survival curves were compared using log-rank test, and a *p*-value of \< 0.05 was considered significant. A Cox proportional hazard regression model was used to estimate hazard ratios (HR). The cut-off points for biomarker concentration were selected as the median value for a given marker.

The variables that appeared to significantly influence the endpoints of the study (OS, LRC and MFS) were selected for a multivariable analysis. Multivariable analysis was performed using the Cox proportional hazard regression model, and the backward selection method was used to select the important variables to be included in the model. In general, missing data were deleted in a univariate analysis and substituted by means in a multivariable study. Several variants of the basic analysis were considered, including subset analysis, considering of the continuous variables instead of dichotomizing them, and substitution of the missing data by means vs. deleting them: the most important outcomes of these variants (particularly those that may influence the qualitative outcome of this research) are presented in the text. Because locoregional recurrence and development of distant metastases are considered competitive reasons for treatment failures only the analysis of OS was performed in the subgroups; likewise, the variants of LRC and MFS analysis are not discussed.

Results {#Sec8}
=======

The outcome in a heterogeneous group of 337 patients {#Sec9}
----------------------------------------------------

The 3-year actuarial overall survival in a whole group of 337 patients was 19.6% (10.1% for palliative treatment and 30.6% for curative treatment), Table [1](#Tab1){ref-type="table"}. Of 16 variables studied age \< 65 years (vs. ≥65 years), female sex (vs. male sex), adenocarcinoma histology (vs. squamous), tumor stage 1--2 (vs. stages T3--4), M0 stage (vs. M+ stage), performance status ZUBROD 0--1 (vs. 2--3), use of curative doses of radiotherapy (vs. doses\< 60 Gy), never smoking status (vs. smoking), and use of chemotherapy (vs. no chemotherapy) were significantly associated with favorable overall survival (Table [1](#Tab1){ref-type="table"}). Of the 6 biochemical markers studied OPN concentration below the median of 104, VEGF concentration below the median of 362 and EPO concentration below the median of 16.1 were also significantly associated with favorable overall survival (Table [3](#Tab3){ref-type="table"}). Table [1](#Tab1){ref-type="table"} and Table 3 present the results of the univariable Cox regression analysis of OS, LRC and MFS and 3-year actuarial OS, LRC and MFS estimates in each of the categories analyzed. The tables also illustrate how the respective variables were dichotomized.

The multivariable analysis (Table [4](#Tab4){ref-type="table"}) revealed that out of several variables studied, six features: namely,cigarette smoking, lack of chemotherapy, palliative doses of radiotherapy, high OPN concentration, advanced T stage and high VEGF concentration, had a highly significant and independent negative influence on overall survival in the group of 337 patients. Figure [1](#Fig1){ref-type="fig"} illustrates the overall survival in a group of patients with non-small cell lung cancer depending on number of the defined risk features (cigarette smoking, lack of chemotherapy, palliative doses of radiotherapy, high OPN concentration, advanced T stage and high VEGF concentration). The differences between the patients with 0--1, 2--4 and 5--6 risk features were highly significant (*p* \< 0.00001). Deletion of the missing data vs. replacing them with means did not change the qualitative outcome of this part of the analysis.Table 4Results of the multivariable study of the influence of selected variables on overall survival in 337 patients with non-small cell lung cancer. Backward selection was used to select the variablesVariableHR (95% CI)*p*-valueEver smoking vs. never smoking3.62 (1.69--7.76)0.000955No chemo vs. chemo2.03 (1.53--2.70)0.000001Palliative RT vs. curative RT2.00 (1.49--2.68)0.000004OPN ≥104 ng/ml vs. OPN \< 104 ng/ml1.67 (1.27--2.20)0.000285T 3--4 vs. T1--21.52 (1.15--2.00)0.003362VEGF1 ≥ 362 pg/ml vs. VEGF\< 362 pg/ml1.51 (1.11--2.05)0.007952Fig. 1Overall survival in the heterogeneous group of patients with non-small cell lung cancer, depending on number of 6 independent risk features (cigarette smoking, lack of chemotherapy, palliative doses of radiotherapy, high OPN concentration, advanced T stage and high VEGF concentration). Missing data were deleted (*n* = 227). The differences between the patients with 0--1, 2--4 and 5--6 risk features are highly significant (*p* \< 0.00001)

Consideration of continuous variables, instead of dichotomous variables, revealed, however, that in a multivariable analysis of overall survival, the VEGF concentration lost an independent significant prognostic influence on overall survival in favor of patient age. The variables remaining significant in this model were: OPN concentration (*p* \< 0.00001), intent of radiotherapy (*p* = 0.00002), smoking status (*p* = 0.0007), use of chemotherapy (*p* = 0.0001), T stage (*p* = 0.003) and patient age (*p* = 0.02). Such an outcome can be explained by the correlation of VEGF and smoking (higher VEGF in smokers) and T stage (increase of VEGF concentration in advanced cases). Additionally, VEGF concentrations tended to be log-normally distributed. When logarithmic transformation of the VEGF concentration was applied, the significance of logarithmically transformed VEGF measurement increased, approaching the threshold for significance in a multivariable model.

Four variables (adenocarcinoma, use of curative doses of radiotherapy, never smoking status, use of chemotherapy) were significantly associated with favorable LRC. A low PDGF concentration (\< 249 pg/ml) was also associated with favorable LRC, but this was largely due to the correlation of PDGF concentration with other prognosticators (tumor pathology, T stage). The multivariable analysis of dichotomized variables revealed that only the use of curative radiotherapy and smoking status were significantly and independently associated with LRC.

Of five variables that significantly influenced MFS in the univariable study (T stage, M stage at diagnosis, use of curative radiotherapy use of chemotherapy, and EPO concentration) only the use of palliative radiotherapy significantly and independently influenced MFS (*p* \< 0.00001, HR = 3.45), with patients receiving palliative treatment at higher risk for developing distant metastases.

The outcome in a subset of patients with curative radio-chemotherapy or radiotherapy {#Sec10}
------------------------------------------------------------------------------------

The patients who were treated with curative radio-chemotherapy or radiotherapy (*N* = 148) created an important, distinct, and relatively homogeneous subset, among the patients studied. Most of the patients in this group were administered induction chemotherapy (131/148, 88.5%), and 17 individuals (11.5%) had radiotherapy alone. The 3-year actuarial overall survival in this group was 30.6% and was significantly influenced by the following variables: gender, pathology, N-stage, smoking status, VEGF concentration, and EPO concentration (Table [5](#Tab5){ref-type="table"}). The 3-year actuarial overall survival was particularly favorable in never smoking patients (64.2%) and in patients with adenocarcinoma (51.0%). The multivariable analysis revealed a significant and independent influence on survival of the following dichotomized variables:pathology (squamous vs. nonsquamous, *p* = 0.003, HR 0.52, 95% CI 0.33--0.80)EPO concentration (\< 16.1 vs ≥16.1, *p* = 0.001, HR = 2.33, 95% CI 1.37--3.95)VEGF concentration (\< 362 vs. ≥362, *p* = 0.007, HR = 1.87, 95% CI 1.19--2.96)Table 5Variables that had significant influence on overall survival in a subset of 148 patients with curative radio-chemotherapy or radiotherapy (univariate analysis)VariableCategories (No)3-year OS*p*-value\
*(HR)*GenderM11125.6%**0.02**F3745.0%***(0.58)***Pathologysquamous9022.0%**0.005 \***adeno2251.0%***(0.42)***NOS3639.9%N stage0--14018.8%**0.02**2--310734.4%***(0.60)***N/A1Smoking statusnever1264.2%**\< 0.04**ever13628.2%***(2.76)***VEGF (*n* = 125)\< 362 pg/ml6238.7%**0.006**≥362 pg/ml6322.7%***(1.89)***EPO (*n* = 96)\< 16.1 mlU/ml5140.3%**0.008**≥16.1 mlU/ml4515.9%***(2.02)***\*comparison between squamous-cell cell cancer and adenocarcinoma

Figure [2](#Fig2){ref-type="fig"} illustrates the influence of these variables on overall survival in the analyzed subset.Fig. 2Influence of tumor pathology (**a**), EPO concentration (**b**) and VEGF concentration (**c**) on overall survival in a group of 148 patients with non-small cell lung cancer treated with curative radio-chemotherapy or radiotherapy. The differences in overall survival are highly significant (*p* = 0.005; *p* = 0.008; *p* = 0.006 in groups **a**, **b**, **c** respectively). Median EPO and VEGF concentration was selected as a cut-off

The prognostic significance of blood markers vs. pathology of the tumor {#Sec11}
-----------------------------------------------------------------------

Tumor pathology had a major influence on overall survival both in a whole group of 33 patients in the subset treated with curative intent (Table [1](#Tab1){ref-type="table"}, Table [4](#Tab4){ref-type="table"}). For this reason, the prognostic value of the markers tested was analyzed in subsets that were uniform with respect to tumor pathology.

In the subset of patients with squamous cell cancer (*N* = 206) OPN had a highly significant impact on overall survival (*p* \< 0.0001; HR 2.09; 95% CI, 1.468--2.99), (Fig. [3](#Fig3){ref-type="fig"}a). The EPO concentration also appeared to have a significant influence (*p* = 0.019; HR = 1.60; 95% CI, 18--2.36). However, an influence of VEGF and HMGB1 did not appear significant (*p* = 0.08, *p* = 0.90, respectively).Fig. 3Influence of OPN concentration on overall survival in a group of 171 patients with squamous-cell cancer (**a**) and 44 patients with adenocarcinoma (**b**). The difference in overall survival according to biomarker concentration is highly significant among the patients with squamous cell cancer (*p* \< 0.0001), but not among the patients with adenocarcinoma. 0.18

In contrast, in a subset of patients with nonsquamous histology (*N* = 131), only VEGF had a significant influence on survival (*p* = 0.02; HR = 1.78; 95% CI, 1.08--2.95), while OPN, EPO and HMGB1 did not appear to have a significant influence (*p* \> 0.05). A similar qualitative outcome was found among the patients with adenocarcinoma (*N* = 44): VEGF tended to influence survival (*p* = 0.10), while the other markers did not appear to have a significant influence (Fig. [3](#Fig3){ref-type="fig"}b).

Discussion {#Sec12}
==========

Despite of recent developments in therapy for advanced non-small cell lung cancer the overall survival in unselected groups of patients remains poor with a median of 1.3 years in the present series of 337 patients. The unfavorable prognosis does not, however, refer to all of the advanced cases. The median survival among the patients with curative radio-chemotherapy or radiotherapy was 2.1 years, and the 3-year survival in this group was 30.6%. This survival was further improved considering well-defined subsets of patients with curative treatment, particularly those with favorable prognostic features (Fig. [2](#Fig2){ref-type="fig"}).

Evaluation of the prognosis in routine clinical practice is, at present, based mostly on the stage of disease, tumor pathology and the ability to deliver curative doses of radiotherapy. The present analysis shows, however, that the use of blood serum proteins as biomarkers can considerably improve the prognostic ability of clinicians. When dichotomized, OPN and VEGF concentration and smoking status of the patients, (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}, Table [3](#Tab3){ref-type="table"}) appeared among the factors that strongly influence the prognosis. Interestingly, the prognostic utility of the blood serum markers as measured by the respective hazard ratios is comparable to the strongest clinical prognosticators known. It is not surprising that out of several markers studied OPN and VEGF appeared to be of greatest interest: both are related to tumor hypoxia, a factor that has major influence on outcome in radiotherapy. An independent prognostic influence of VEGF on survival seems, however, smaller than that of OPN. When analyzed as a continuous variable VEGF lost its independent prognostic value in favor of the other variables. This was, most likely, due to the correlation of VEGF with smoking status and T stage. Additionally, the distribution of VEGF measurements appeared log-normal, contributing to such outcomes. Clearly, the diverse outcomes of the basic analysis options show the limitations of the present study. Such diverse outcomes may, however, also indicate that blood biomarkers may, in some situations, become surrogates of clinical or pathological prognosticators that were unintentionally or deliberately not included in the model.

Most of the patients in the present series were current or former smokers; a small subset of the never smokers had, however, a very favorable prognosis (median survival not reached). While the molecular analysis of tumors was not systematically performed in the present series the data from the other series suggest a distinct characteristic of nonsmokers including the prevalence of tumors with EGFR mutations \[[@CR32]\]. These features were linked to higher radiosensitivity of the tumors that might have been reflected by favorable survival in the present series of patients treated with radiotherapy. By contrast, smoking was related to a high frequency of KRAS mutations, which is a feature linked to impaired prognosis in patients treated with radiotherapy \[[@CR33]\].

The subset of patients with curative radio-chemotherapy or radiotherapy is considerably more clinically homogeneous, than the unselected group. The present analysis suggests the prognostic utility of tumor pathology, EPO concentration and VEGF concentration that were dichotomized based on the median values. In particular, adenocarcinoma pathology favorably influenced survival (3-year survival of 51%; median survival of 3.1 years). The lack of independent prognostic significance of OPN in patients with curative radio-chemotherapy or radiotherapy was elucidated by the analysis of the prognostic significance of blood markers vs. pathology of the tumor; the utility of OPN as a prognostic marker appeared to be restricted to the patients with squamous histology. For patients with nonsquamous histology treated with curative radio-chemotherapy or radiotherapy VEGF appeared to be the most useful marker. This finding shows that the utility of given markers useful in a heterogeneous group of patients is not necessarily reproduced in more homogenous subsets.

The data presented conform reasonably well with large studies on the prognostic significance of plasma biomarkers in radiotherapy for non-small cell lung cancer \[[@CR8]--[@CR10]\]. Ostheimer et al. \[[@CR8]\] analyzed a group of 55 patients treated with curative radiotherapy or radio-chemotherapy. They analyzed plasma concentrations of OPN, VEGF and CA IX (carbonic anhydrase IX). The study demonstrated that high pretreatment plasma levels of OPN, CA IX and VEGF were correlated with impaired prognosis in M0-stage NSCLC patients receiving radical radiotherapy, which is in a good concordance with the present results.

Dehing et al. \[[@CR9]\] analyzed the survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone. The analysis included the concentration of lactate dehydrogenase, C-reactive protein, osteopontin, carbonic anhydrase IX, interleukin (IL) 6, IL-8, carcinoembryonic antigen (CEA), and cytokeratin fragment 21--1. The statistical model was built on 106 patients and validated on 52 individuals. The performance of the prognostic model for survival that included clinico-pathological features improved markedly by adding two blood biomarkers: CEA and IL-6. We note that only 35% of the patients in this study had squamous-cell cancer. Therefore, we believe, that considering the outcome of the present study, the data presented by Dehing et al. \[[@CR9]\] may not preclude the prognostic significance of osteopontin in patients with squamous-cell histology.

Recently Walker et al. \[[@CR10]\] presented data on the discovery and validation of predictive biomarkers of survival for non-small cell lung cancer patients undergoing radical radiotherapy. Over 650 proteins were detected and quantified using a mass spectrometry discovery proteomics platform. Plasma samples from patients before and during radiotherapy who had survived over 18 months were compared to the same time points from patients who survived less than 14 months. Two of the proteins studied CRP (C-reactive protein) and LRG1 (leucine-rich-alpha-2 glycoprotein) gave a highly significant indication of extended survival. We note, however, that contrary to the studies by Ostheimer et al. \[[@CR8]\], and Dehing et al. \[[@CR9]\] and the present investigation, the analysis did not incorporate clinically relevant variables such as age, stage, and performance of the patients. Therefore, the proteins of interest (CRP and LRG1) should be confronted with other variables influencing survival in the future studies to evaluate their possible independent prognostic utility.

Conclusions {#Sec13}
===========

Blood serum proteins appear to be clinically useful prognosticators of overall survival in radio-chemotherapy and radiotherapy for non-small cell lung cancer. In unselected groups, heterogeneous with respect to the intent of treatment and tumor histology the dichotomized concentration of OPN and VEGF emerged among the strongest independent prognostic factors next to smoking status, use of chemotherapy, doses of radiotherapy and tumor stage. In particular, the OPN concentration exhibited a prognostic power comparable to or higher than that of the strongest known clinical prognosticators.

When dichotomized, VEGF and EPO concentrations as well as tumor histology were found to be independent prognostic factors among the patients treated with curative doses of radiotherapy. The utility of OPN as a prognostic marker appeared to be restricted to patients with squamous histology. For patients with nonsquamous histology VEGF appeared to be the most useful marker.

CTV

:   Clinical target volume

EPO

:   Erythropoetin

GTV

:   Gross tumor volume

HMGB1

:   High mobility group box 1 protein

IGF-1

:   Insulin-like growth factor 1

LRC

:   Locoregional control

MFS

:   Metastases-free survival

OPN

:   Osteopontin

OS

:   Overall survival

PDGF

:   Platelet-derived growth factor

PET/CT

:   Positron emission tomography/computer tomography

VEGF

:   Vascular endothelial growth factor
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